Development of a new DNA array-based diagnostic system (IBDchip) to predict clinical course, development of complications, and response to therapy in patients with inflammatory bowel disease (IBD)

Objective

Inflammatory bowel disease (IBD) includes Crohn's disease (CD) and ulcerative colitis (UC). Both are increasingly common, chronic illnesses, currently affecting nearly 1 million patients in Europe. CD and UC affect patients early in life, seriously impairing their quality of life and resulting in enormous personal, social, and economic costs.There is evidence suggesting that genetic factors play a key role in IBD pathogenesis, pointing towards a polygenic mode of inheritance for CD and UC. However, to date studies have only addressed the influence of single mutations on IBD, resulting in a poor prediction of clinical course or response to therapy in individual patients. The IBDchip Project will develop an easy to use DNA array. This non-invasive tool will allow the simultaneous analysis of around 100 relevant mutations to predict the clinical evolution, the risk of developing IBD-related complications, and the likelihood of responding to certain drugs of each IBD patient. The project will have four main phases of work: 1. Two main retrospective studies including 1000 CD and 1000 UC patients across Europe. These studies will be aimed at defining the best combination of mutations resulting in an optimal prediction of each clinical outcome. 2. Three prospective studies specifically designed to address prediction of patients' response to immunosuppressive and anti-TNF therapies, which will validate the information provided by the retrospective studies. 3. A technical optimization process of the IBDchip, expected to result in a faster, cheaper, and easier to use tool. 4. Finally, the exploration of pathways to clinical service, ethical and legal issues, and cost-effectiveness of the IBDchip, to ensure its uptake in routine clinical practice. The main outcome of this project will be to provide doctors, for the first time, with a non-invasive, predictive tool to optimize treatment in IBD patients, thus resulting in better clinical outcomes and cost-effectiven'

Programme(s)

• FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006.

Topic(s)

• LSH-2005-1.2.2-4 - Development of new diagnostics

Call for proposal

FP6-2005-LIFESCIHEALTH-7
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

CONCORCI INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER

Address

Villarroel 170
Barcelona
Spain

Participants (8)

PROGENIKA BIOPHARMA, S.A.

Spain

Address

Parque Tecnológico De Zamudio, Edificio 801
Derio

INNOPSYS

France

Address

Parc D'activités Activestre
Carbonne

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

Address

University Offices, Wellington Square
Oxford

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

Address

Oude Markt 13
Leuven

UNIVERSITY HOSPITAL SCHLESWIG-HOLSTEIN

Germany

Address

Brunswiker Str. 10
Kiel

GENERAL TEACHING HOSPITAL IN PRAGUE

Czechia

Address

U Nemocnice 2
Prague 2

HUMANITAS MIRASOLE SPA

Italy

Address

Via Manzoni, 56
Rozzano

VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG

Netherlands

Address

De Boelelaan 1117
Amsterdam